RT Journal Article
SR Electronic
T1 Coronavirus Disease 2019 and Nasal Conditions: A Review of Current Evidence
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 1409
OP 1417
DO 10.21873/invivo.12393
VO 35
IS 3
A1 ISAO SUZAKI
A1 HITOME KOBAYASHI
YR 2021
UL http://iv.iiarjournals.org/content/35/3/1409.abstract
AB The nasal epithelium expressing enriched angiotensin-converting enzyme II (ACE2), the key cell entry receptor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), could serve as the first barrier to protect the airway from viral infection. Recent studies have demonstrated that higher viral loads were detected in the nasal cavity than the pharynx in coronavirus disease 2019 (COVID-19) patients, and otolaryngologists should carefully consider infection prevention in clinical practice for the treatment of nasal conditions. Moreover, several studies have indicated that anosmia is one of the clinical characteristics of COVID-19, but the precise prevalence and mechanism remain unclear. Thus far, comorbidity of allergic rhinitis and chronic rhinosinusitis do not seem to be a major risk factor for severe COVID-19. However, we should develop strategies in clinical practice for the treatment of nasal diseases during the pandemic. In this article, we reviewed current evidence of the relationship between COVID-19 and nasal conditions, such as COVID-19-related olfactory dysfunction, allergic rhinitis, and chronic rhinosinusitis.